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Diabetic glomerulopathy has been linked to shifts in balance
between the synthetic and degradative pathways of the
glomerular basement membrane (GBM), a key player in the
permselectivity properties of the glomerular wall. The goal of
this study was to trace the expression and localization of
membrane type-1 metalloprotease (MT1-MMP) and its
activating enzyme furin, key proteins involved in basement
membrane turnover, in short- and long-term diabetic rat
renal tissues. Quantitative immunogold was carried out for
MT1-MMP and furin and their expression was evaluated in
renal tissues of young and old, control and diabetic rats. To
corroborate immunocytochemical findings, Western blots
were performed on glomerular lysates. Electron microscopy
revealed that the overall expression of MT1-MMP and furin is
reduced in plasma membranes of all glomerular cell types of
old normoglycemic animals, a phenomenon that is
exacerbated in long-term diabetic animals. This observation
supports the prevailing theory that diabetes fosters
acceleration in the aging process. Interestingly, while
biochemical results confirmed a decrease in MT1-MMP
expression, an increase in furin was observed.
Immunocytochemical studies resolved this discrepancy by
tracing the increased furin expression in endoplasmic
reticulum and Golgi membranes of podocytes, indicating that
furin is retained in the secretory pathway in a diabetic
environment. Disturbances at the molecular level of the
otherwise tightly regulated MT1-MMP/furin interactions
found at the cell surface must account for a lack in
extracellular matrix remodeling, increased deposition of GBM
material, and loss of glomerular filtration integrity.
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As the ultimate site of plasma filtration, the glomerular wall
plays a vital role in maintaining proper permeability for the
production of the primary urine.1 The integrity of the
glomerular wall in terms of structural organization and
protein composition is the cornerstone of intact permselec-
tivity. Obvious morphological changes associated with the
onset of diabetes and loss of permselectivity include
thickening of the glomerular basement membrane (GBM),
expansion of the mesangial matrix, and podocyte efface-
ment.2–4 The molecular era of the past two decades has
allowed us to witness a wave of information concerning the
proteinacious composition of the main filtrating constituents
of the glomerular wall, notably the endothelial fenestrations,
the GBM, the slit diaphragms at the junction of podocytes,
and the mesangial matrix.1,5,6 It has thus recently been
possible to identify the molecular mechanisms responsible
for progressive glomerulosclerosis at an ultrastructural level.
Electron microscopy employing the immunogold techni-
que as an investigative tool has played an essential role
tracing the modifications in molecular composition of
glomerular wall components in hyperglycemic environ-
ments.7–10 Bendayan’s group in particular, followed the
expression and localization of certain key molecular con-
stituents of the GBM and reported that while most molecules
remained intact, there were changes in type IV collagen
distribution and expression in diabetic rats.9,11 Indeed the
importance of collagen deposition and accumulation in the
thickening of the GBM cannot be overemphasized.5,12,13 One
of the avenues leads to the identification and localization of
the enzymes responsible for basement membrane turnover, a
process which proves integral to the maintenance of intact
glomerular filtration. The amount and composition of
extracellular matrix (ECM) depends on the delicate inter-
actions existing between synthetic and degradative pathways,
and various forms of glomerular disease are characterized by
shifts in this balance.14,15
The matrix metalloproteases (MMPs) are a large family of
zinc endopeptidases widely recognized as crucial mediators
in ECM turnover.16 The membrane type-I metalloprotease
distinguishes itself as a membrane-bound enzyme capable of
exerting its cleavage activities from the vantage point of the
cell surface.17 Osenkwoski et al. underline the regulatory
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benefits of membrane type-1 metalloprotease (MT1-MMP)’s
strategic positioning at the membrane. Localization of MT1-
MMP at the cell membrane is perfect for pericellular proteo-
lysis allowing for a new set of substrate targets, distinctive
interactions with tissue inhibitor of metalloproteinases, and a
non-conventional mechanism of regulation involving enzyme
internalization, processing, and ectodomain shedding.18,19
The primary function of MT1-MMP is to degrade matrix-
associated molecules either directly or via the activation of
downstream MMPs.20 Animal knockout models have shown
that MT1-MMP is the only MMP known to be essential for
survival,18 a fact that is emphasized by its wide array of
substrates including type IV collagen.20 The dual role of
MT1-MMP as activator of other MMPs capable of initiating
activation of zymogen cascades, and as direct cleaver of ECM
components, only underscores its vital function as an ECM
remodeler and singles it out as a potential therapeutic
target.15,20
Cleavage of the propeptide region is sine qua non for
MT1-MMP activation and subsequent proteolytic activity.
Yana and Weiss21 demonstrated the existence of a proprotein
convertase–MT1-MMP axis allowing for the unmasking of
MT1-MMP’s catalytic domain and conversion into a
catalytically active species. This was carried out through the
identification of the RX(K/R)R basic motif in the pro-
peptide region of MT1-MMP, a sequence of amino acids
that can potentially be recognized by the proprotein
convertase family of subtilisin-like proteases. Indeed, in vitro
studies using MT1-MMP deletion mutants confirmed that
furin is capable of cleaving the pro-MT1-MMP zymogen.21
It is thus apparent that cooperative interactions bet-
ween proprotein convertases and membrane-anchored
MMPs play an important role in regulating the remodeling
of ECM.
Furin is an endoprotease involved in the proteolytic
activation of a large variety of proprotein substrates in
secretory pathway compartments.22 The importance of furin
as a proprotein convertase capable of processing a wide range
of precursors cannot be overemphasized as it has been shown
to be ubiquitous in most cell types.23 Specific amino-acid
motifs identified in furin’s cytoplasmic tail have shown to
target furin to different cellular compartments; a finding
which has shed light on furin trafficking between the trans-
Golgi network, endosomal compartments, and the cell
surface.24–26 The physiological role of furin in glomerular
cells was well characterized by Mayer et al.26 who co-localized
the protein with pro-MT1-MMP in the biosynthetic pathway
and traced their translocation beyond the trans-Golgi
network onto the cell surface. Mayer et al. propose an
MT1-MMP activation axis at podocytic and endothelial
abluminal membranes facing the GBM for a type of focalized
pericellular proteolysis, which characterizes the integrated
functions of cellular and extracellular elements involved in
tissue remodeling.26 The purpose of our study was to extend
this knowledge of interactions among cell surface proteins
mediating GBM turnover in normal cells, to their potential
modification of expression and/or deregulation in diabetic
rat renal tissues.
RESULTS
The most striking observation by electron microscopy was
the pronounced thickening of the GBM in tissues of
12-month-old hyperglycemic animals and to a lesser degree
in tissues of their age-matched normoglycemic animals. No
prominent morphological differences were noted between
2-month-old animals, normal as well as diabetic.
Immunolabeling
In all tissues, gold particles revealing membrane MT1-MMP
antigenic sites were found over luminal and abluminal
podocyte plasma membranes, in particular at the slit
diaphragms, luminal and abluminal endothelial cell mem-
branes (Figure 1), as well as over mesangial cell plasma
membranes. No obvious changes were detected in tissues of
diabetic animals. However, a specific look at the slit
diaphragm region unmistakably revealed a drop in MT1-
MMP labeling from tissues of 2-month-old control and
diabetic rats to tissues of their 12-month counterparts. Gold
particles were seen labeling the GBM. Labeling was virtually
absent in the urinary space and capillary luminae (Figure 1).
Morphometrical analyses confirm subjective observations
(Table 1). There is an overall decrease in MT1-MMP labeling
with age and this decline is most striking in diabetic
conditions. Labeling densities in podocytic abluminal and
luminal plasma membranes and endothelial abluminal and
luminal membranes of old diabetic animals are significantly
less than in young control animals. Overall, abluminal and
luminal podocyte membrane labelings appear to decrease by
little less than half in tissues of old versus young animals.
Similarly, there is a steady decline in MT1-MMP labeling in
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Figure 1 | Electron micrographs of (a) short-term control and
(b) long-term diabetic rat renal tissues. Colloidal gold labeling
demonstrates the presence of MT1-MMP in the glomerular wall.
There seems to be a significant decrease in labeling in tissues of
diabetic animals. Thickening of the GBM in the tissues of the diabetic
animal (b) is evident. US¼ urinary space, P¼podocyte, CL¼ capillary
lumen. Bars¼ 0.25 mm.
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the slit diaphragm regions along with age and diabetes.
Labeling in the mesangial cell plasma membranes of young
normal and diabetic rats is quite low but increases in old rat
tissues, especially in the old diabetic ones. Antibody control
test measurements revealed no significant labeling
(0.01470.001 particles/mm), confirming the specificity of
our results.
Furin immunolabeling was also found over both luminal
and abluminal membranes of podocytes and endothelial cells
as well as over the mesangial cell plasma membranes
(Figure 2). Labeling of furin in luminal and abluminal
endothelial plasma membranes of diabetic rat tissues seemed
to be lower than in the non-diabetic ones. There also
appeared to be less furin over luminal and abluminal
podocytic cell plasma membranes, and in the slit diaphragm
regions of 12- versus 2-month-old rat tissues. Furin in the
glomerular wall was in higher concentrations in luminal
plasma membranes of podocytes and slit diaphragm junc-
tions, especially in normal rat tissues, while other analyzed
regions seemed to be more sparsely decorated. Particles were
also found in mesangial cell plasma membranes but they were
few in number.
Morphometrical evaluations are in agreement with above
observations (Table 2). Gold particles numbered over one
particle per micron in 2- and 12-month-old, abluminal and
luminal endothelia of control rat and decreased in diabetic
age-matched counterparts. Labeling densities over abluminal
and luminal podocytic plasma membranes are considerably
less in old and diabetic rat tissues when compared to tissues
of 2-month-old animals. In the slit diaphragms, a twofold
decrease occurred between young normal rats and old
diabetic ones. Total number of gold particles in mesangial
plasma membranes remained low in both normal and
diabetic animals. Antibody control testing yield very low
values (0.01770.001 particles/mm), which confirms the
specificity of labelings.
GBM immunolabelings for MT1-MMP and furin are
reported in Table 3. Significant decreases are found only after
12 months of diabetic condition.
Western blotting
Membranes incubated with anti-MT1-MMP revealed three
bands of different molecular weights (Figure 3). The heaviest
band at 63 kDa represents the latent precursor proprotein
before activation by cleavage.27 Bands at 57 and 44 kDa were
also observed, the former being the active and membranous
version of the protein and the latter representing the inactive
ectodomain form.18 Heavy signaling of the 63 kDa latent
precursor is seen in young, non-diabetic rat tissue lysates.
The intensity of the signal decreases sharply in samples from
young diabetic animals and nearly disappears in old diabetic
and non-diabetic ones. A similar pattern is observed for the
57 kDa active form of MT1-MMP. In contrast, the 44 kDa
band signaling intensity steadily increases from young
control to old diabetic animal glomerular lysates, suggesting
a marked propensity for autocatalytic degradation of the
protein into its inactive form. This was confirmed by
densitometry measurements (Figure 3).
Western blotting of glomerular lysates revealed a band at
98 kDa which corresponds to mature rat furin (Figure 4).28
Only very faint signaling could be observed in tissues of the
2-month-old control and diabetic animals, whereas denser
bands appeared in 12-month-old control and diabetic rat
tissue samples. This was confirmed by densitometry mea-
surements (Figure 4). These results signaled a discrepancy
between electron microscopic observations and biochemical
results involving furin. This prompted us to carry on an
additional morphological investigation of the intracellular
expression of furin.
Table 1 | Quantitative evaluation of immunogold labeling for MT1-MMP over the glomerulus (gold particles per lm, mean
values7s.e.m.)
Endothelial cells Podocytes
Mesangial cells
Animals Abluminal membrane Luminal membrane Abluminal membrane Luminal membrane Slit diaphragm Plasma membrane
2 months, control 0.6870.14 0.9170.19 1.1170.20 1.8770.23 1.2970.25 0.2270.08
2 months, diabetic 0.6270.16 0.7770.22a 0.8470.17a 1.0670.16a 0.9970.17a 0.2370.08
12 months, control 0.5670.11a 0.5570.16a 0.5470.13a 0.8270.17a 0.5370.14a 0.5270.12a
12 months, diabetic 0.4870.16a,b 0.7970.22a,c 0.4670.15a,b 0.7470.16a,b 0.4970.19a,b 1.1470.18a,b,c
aSignificantly different from the corresponding 2 months control values, Po0.05.
bSignificantly different from the corresponding 2 months diabetic values, Po0.05.
cSignificantly different from the corresponding 12 months control values, Po0.05.
MT1-MMP, membrane type-1 metalloprotease.
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Figure 2 | Electron micrographs of (a) short-term control and
(b) long-term diabetic rat renal tissues. Colloidal gold labeling of
furin reveals less labeling in the glomerular wall of the diabetic
animal. US¼ urinary space, P¼podocyte, CL¼ capillary lumen.
Bars¼ 0.25 mm.
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MT1-MMP and furin in the ER and Golgi
MT1-MMP immunolabeling was found over endoplasmic reti-
culum (ER) and Golgi membranes (Figure 5). There were greater
amounts of gold particles in 2-month-old normoglycemic and
hyperglycemic rat tissues than in their 12-month-old counter-
parts and a quantitative evaluation of these regions reveals a
twofold decrease in labeling (Table 4).
Furin immunolabeling was also found over ER mem-
branes and Golgi cisternae of podocytes (Figure 6). Differ-
ences in labeling were striking between young and old rat
tissues, and morphometric countings do report a significant
increase in furin immunolabeling in 12-month-old diabetic
and non-diabetic rat tissues in both ER and Golgi, when
compared to the young animals (Table 5). In all instances,
Table 2 | Quantitative evaluation of immunogold labeling for furin over the glomerulus (gold particles per lm, mean
values7s.e.m.)
Endothelial cells Podocytes
Mesangial cells
Animals Abluminal membrane Luminal membrane Abluminal membrane Luminal membrane Slit diaphragm Plasma membrane
2 months, control 1.0570.14 1.3870.15 1.1170.16 1.9070.21 1.3370.18 0.2070.06
2 months, diabetic 0.8370.13a 0.7270.12a 0.6470.12a 0.9570.15a 0.9970.19a 0.2170.04
12 months, control 1.1570.22b 1.2270.34b 0.6070.16a 0.9770.19a 0.7670.17a 0.3470.05a,b
12 months, diabetic 0.5470.11a,b,c 0.6370.13a,c 0.5770.11a 0.9970.18a 0.6470.14a,b 0.3470.08a,b
aSignificantly different from the corresponding 2 months control values, Po0.05.
bSignificantly different from the corresponding 2 months diabetic values, Po0.05.
cSignificantly different from the corresponding 12 months control values, Po0.05.
Table 3 | : Quantitative evaluation of immunogold labelling
for MT1-MMP and furin over the GBM (gold particles per lm2,
mean values7s.e.m.)
MT1-MMP Furine
2 months control 1.3770.24 1.8070.33
2 months diabetic 1.1270.14 2.5070.27
12 months control 1.0570.09 1.4270.20a
12 months diabetic 0.6170.08a,b,c 1.5070.15a
aSignificantly different from the corresponding 2 months diabetic value, Po0.05.
bSignificantly different from the corresponding 2 months control value, Po0.05.
cSignificantly different from the corresponding 12 months control value, Po0.05.
GBM, glomerular basement membrane; MT1-MMP, membrane type-1 metalloprotease.
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Figure 3 | Western blot analysis of MT1-MMP in glomerular
lysates: (a) 2 months control, (b) 2 months diabetic, (c) 12
months control, (d) 12 months diabetic. Varying band intensities
were found at three molecular weights: the 63 kDa pro-form, the
57 kDa active form, and the 44 kDa inactive form. Graph summarizes
densitometry evaluations (N¼ 4), D¼density (arbitrary units).
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Figure 4 | Western blot analysis of furin in glomerular lysates: (a)
2 months control, (b) 2 months diabetic, (c) 12 months control,
(d) 12 months diabetic. The furin band can be seen at 98 kDa. Graph
summarizes densitometry evaluations (N¼ 4), D¼density (arbitrary
units).
G
RER
RER
Figure 5 | Electron micrograph of 2-month control rat renal tissue
Golgi region of a podocyte. Gold particles labeling MT1-MMP are
found in rough ER (RER) and Golgi (G) cisternae. Bar¼ 0.25 mm.
Table 4 | Quantitative evaluation of immunogold labeling for
MT1-MMP over podocytic cellular compartments (gold
particles per lm, mean values7s.e.m.)
Animals ER Golgi apparatus Mitochondria
2 months, control 0.8570.06 0.8970.09 0.1570.09
2 months, diabetic 0.7770.05 0.8670.1 0.1670.12
12 months, control 0.4470.04a,b 0.4570.1a,b 0.1970.03
12 months, diabetic 0.4270.04a,b 0.5570.08a,b 0.1870.02
aSignificantly different from the corresponding 2 months control values, Po0.05.
bSignificantly different from the corresponding 2 months diabetic values, Po0.05.
ER, endoplasmic reticulum; MT1-MMP, membrane type-1 metalloprotease.
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background labeling measured in neighboring mitochondria
remained low for both antigens (Tables 4 and 5).
DISCUSSION
This study looked to further characterize the expression of
some key proteins of the glomerular wall associated with
diabetes. The MT1-MMP and its activating enzyme furin play
pivotal roles in ECM turnover enticing us to evaluate their
expression in diabetic rat renal tissues. By analyzing tissues of
short- and long-term diabetic animals, we found that both
enzymes exhibit a decrease in expression in all evaluated cell
plasma membrane regions along with age, an alteration that
became more pronounced in diabetic conditions. These
observations confirm a recurring theme in the study of long-
term diabetes, one which proposes that the presence of
diabetes accelerates the aging process.9,29–31 The conse-
quences of aging and diabetes are most evidently observed
in the thickening of the GBM due to increased deposition
and accumulation of ECM proteins. In the present study, we
found two factors which most likely exacerbate GBM
thickening: a decrease in MT1-MMP, which cleaves a wide
array of ECM substrates, concomitant with a decrease in
furin, a proprotein convertase which activates MT1-MMP.
With the goal of corroborating immunocytochemical
findings, Western blots were performed on glomerular
lysates. Bands revealed three different forms of MT1-MMP;
the pro- and active forms significantly diminished in
intensity along with age and diabetes as expected, whereas
the truncated inactive form increased in signaling intensity.
Furin, on the other hand, gave interesting results. Instead of a
decrease in expression, as found with morphological tools,
the 98 kDa furin band increased in intensity in old normal
and diabetic rat tissues. These findings prompted us to
extend immunocytochemical investigations to the sites of
synthesis and processing of MT1-MMP and furin.
Significant pools of furin and MT1-MMP were seen co-
localized and concentrated within the Golgi apparatus of
podocytic cells as well as over plasma membranes, suggesting
that translocation of pro-MT1-MMP through the secretory
pathway and onto the cell surface is facilitated by furin.26
Furthermore, in this study, furin immunolabeling was found
concentrated over Golgi and ER cisternae of podocytic cell
bodies to a greater extent in old rat renal tissues than in their
young counterparts, a trend that was more significant in
diabetic conditions. Therefore, there is a possibility that furin,
although transcribed and synthesized to a greater degree in a
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Figure 6 | Electron micrographs of furin immunolabeling. Pericytes from (a, c) young control and (b, d) old diabetic animals. (a, b) Illustrate
rough ER (RER), whereas (c, d) illustrate Golgi apparatus. The labelings are drastically increased in tissues of diabetic animals (b, d).
Bars¼ 0.25 mm.
Table 5 | Quantitative evaluation of immunogold labeling for
furin over podocytic cellular compartments (gold particles
per lm, mean values7s.e.m.)
Animals ER Golgi apparatus Mitochondria
2 months, control 0.5970.05 0.4370.07 0.1570.05
2 months, diabetic 0.5570.06 0.4670.07 0.1270.06
12 months, control 0.8570.08a,b 0.6470.07a,b 0.2070.05b
12 months, diabetic 0.8670.08a,b 0.6670.08a,b 0.1970.04b
aSignificantly different from the corresponding 2 months control values, Po0.05.
bSignificantly different from the corresponding 2 months diabetic values, Po0.05.
ER, endoplasmic reticulum.
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high glucose environment, associates with pro-MT1-MMP in
the Golgi but remains trapped in the trafficking pathway. If
furin cannot shuttle pro-MT1-MMP to the cell surface, then it
cannot activate the metalloprotease for focalized pericellular
proteolysis essential to GBM turnover.
Western blot results of MT1-MMP were concomitant with
immunocytochemical findings in that the active form of the
protein is greatly reduced in diabetes. Interestingly, MT1-
MMP is present in the GBM suggesting the existence of a
shed form of the protein. The processes of autocatalysis and
shedding of MT1-MMP were thoroughly explored by Toth
et al.19 in an attempt to elucidate the mechanisms of
regulation governing MT1-MMP activity at the plasma
membrane. They observed how ectodomain shedding
regulates the pericellular and extracellular activities of
MT1-MMP, allowing for either active or inactive truncated
versions of the protein to circulate about and act on the
ECM.18,19 This delicate balance in enzyme activity was
further layered in complexity as mechanisms of processing,
shedding, homodimerization, and endocytosis of the mem-
brane MMP were discovered.18 Autocatalysis of MT1-MMP
at the cell surface is the main mechanism behind the
generation of the 44-kDa species, an inactive degradation
product lacking the catalytic domain. Osenkowski et al.18
emphasize how the presence of this inactive version of the
protein can compete with the full-length enzyme for collagen
binding, reducing collagenolytic activity and cellular invasion
of the collagen matrix. The negative influence exerted by the
44-kDa species over MT1-MMP enzyme-processing activity
may explain how its overabundance in tissues of diabetic
animals, as observed in our biochemical findings, still slows
down ECM turnover.
In a study carried out in 1997, Blanchette et al. brought
attention to the activation loop between transforming growth
factor-beta (TGF-b) and furin. With the promoters regulat-
ing fur gene expression cloned, it was possible to show in rat
synovial cells incubated with TGF-b that this growth factor is
capable of coercing fur gene promoters into augmenting
furin transcription levels.23 In a previous study, furin had
been identified as the converting enzyme responsible for
generating mature TGF-b by cleaving the R-H-R-R sequence
motif.32 The result is an autofeedback loop mechanism, in
which TGF-b upmodulates fur gene expression, which in
turn increases pro-TGF-b maturation.23 The role of TGF-b in
diabetic kidney disease is well documented.14,15,33–35 In cells
treated with high glucose concentrations, a significant rise in
TGF-b mRNA expression is observed as early as 24 h after the
onset of hyperglycemia.14 As a result, the enzyme is capable
of instigating factors that promote ECM accumulation such
as increasing the synthesis of ECM components while
simultaneously downregulating genes that promote matrix
degradation.33–36 And so, a potential new link between furin
and diabetes is made. If the expression of TGF-b is
upregulated in diabetic conditions, then active TGF-b in
turn increases the transcription of its own activating enzyme
furin. Although furin is overexpressed in a hyperglycemic
environment, as our biochemical results suggest, analysis by
electron microscopy leads us to believe that the enzyme is
retained in the ER and Golgi compartments of the protein-
trafficking pathway. This prevents it from reaching the cell
surface where cleavage of metalloproteases such as MT1-
MMP can occur for GBM maintenance and turnover.
In 1994, Nakamura et al.37 pointed out that the expression
of many metalloproteases was downregulated in streptozo-
tocin-induced diabetic rats. The abnormal gene regulation of
mt1-mmp in particular was eventually linked to TGF-b. In
high glucose conditions, TGF-b expression is increased and
may alter mt1-mmp promoter activity through inhibition.38
Defects at the mt1-mmp gene transcription level in diabetic
conditions thus accounts for the loss of its proteolytic
activities in GBM turnover as inactive species accumulate and
active membrane species are not replenished. The decrease in
MT1-MMP expression in diabetes has been widely reported
in the literature14,15,34,39 and was also observed by electron
microscopy at the level of plasma membranes and Golgi
compartments of glomerular cells in our study.
TGF-b thus reveals itself as a double-edged sword; on the
one hand, it upregulates furin gene transcription and on the
other it downregulates mt1-mmp gene transcription through
indirect interactions with their promoter regions. An
upregulation in furin synthesis by TGF-b does not seem to
compensate for TGF-b downregulation of GBM proteolytic
proteins such as MT1-MMP, and upregulation of ECM
component synthesis like collagen, factors that contribute to
the thickening of the basement membrane as seen in
glomerulosclerosis. As a result, not only does furin have less
of its substrate to cleave, but our electron microscopy results
seem to suggest that the proprotein convertase is retained in
the biosynthetic pathway. To substantiate this proposition,
there is a need for further studies involving other furin
substrates that are also membrane-bound but not down-
regulated in diabetes. If expression of these proteins at the cell
surface is reduced, then evidence for furin retention in the
secretory pathway could be further strengthened.
MATERIALS AND METHODS
Antibodies
The rabbit anti-matrix metalloproteinase-14 (MMP-14 or MT1-
MMP) was from Sigma-Aldrich (Oakville, ON, Canada). Raised
against the N-terminal portion of the enzyme, the antibody tags
both mature and pro-forms of MT1-MMP. Rabbit anti-furin was
from Alexis Biochemicals (Axxora, LLC, San Diego, CA, USA). The
antibody was raised against the N-terminal portion (amino-acid
sequence 187–198).
Animals
Experimental diabetes was induced in 150 g male Sprague–Dawley
rats by an intraperitoneal streptozotocin injection (70 mg/kg body
weight dissolved in 10 mM/l citrate buffer, pH 4.5). Within 48 h,
animals developed a hyperglycemic state which lasted throughout
their lifetime. Glycemia was assessed on a monthly basis with Accu-
Check test strips and blood glucose meters (Roche Diagnostics,
Laval, QC, Canada), while glycosuria measurements were carried
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out weekly using UriScan test strips (VWR International, Montreal,
Canada). Glycemic states at death of 2- and 12-month-old diabetic
rats averaged 25.374.3 mmol/l (N¼ 4) and 27.474.0 mmol/l
(N¼ 4), respectively, versus 5.670.8 mmol/l (N¼ 4) and 6.77
1.2 mmol/l (N¼ 4) for their age-matched controls. Four experi-
mental groups were created, each comprising of four animals, two
were composed of streptozotocin-injected animals, which main-
tained hyperglycemia for 2 and 12 months, and two were their age-
matched controls. Animals were housed and handled according to
the guidelines from the Canadian Council on Animal Care.
Glomerular isolation
Animals were anaesthetized with urethane. Upon excision, entire
kidneys were immediately recovered in phosphate-buffered saline
and subjected to sequential sieving methods to separate glomeruli.40
Isolated glomeruli were washed and suspended in freshly made
lysis buffer,40 homogenized, and kept on ice for 1 h. Homogenates
were then centrifuged (2500 r.p.m.) for 20 min at 41C to remove
non-solubilized material. The supernatant carrying membranous
proteins MT1-MMP and furin were used for our studies. Protein
quantitation was carried out using the bicinchoninic acid method
(Protein Concentration Assay, Pierce, Rockford, IL, USA) with
bovine serum albumin as a standard. Samples were aliquoted at
concentrations of 40 mg and stored at 801C until needed.
Immunocytochemistry
Small tissue fragments were rapidly fixed by immersion in a 4%
paraformaldehyde–lysine–periodate solution for 2 h at 41C. They
were rinsed in 0.1 mol/l phosphate buffer, dehydrated in methanol,
and embedded at 301C in Lowicryl K4M.41 Ultrathin sections were
mounted on Parlodion-carbon-coated nickel grids for immuno-
cytochemistry.
MT1-MMP and furin antigenic sites were revealed using the
corresponding polyclonal antibodies in combination with the
protein A–gold complex on a post-embedding immunocytochemical
approach as described previously.41 The anti-MT1-MMP was used
at 1:50 and anti-furin at 1:10, both overnight at 41C. Incubation
with protein A-gold (10 nm) was carried out for 30 min at room
temperature. The tissue sections were stained with uranyl acetate
and observed with a Philips 410SL electron microscope. Specificity
of immunolabelings was assessed by incubating tissue sections with
the protein –A–gold complex, omitting the primary antibody step.
Competition experiments were also carried out using antigen-
adsorbed antibodies.
Precise localization and quantification of both MT1-MMP and
furin antigens over glomerular tissue were carried out on electron
micrographs with Clemex Vision Analysis unit. Pictures were
recorded at original magnification  21 000. Forty pictures were
taken for each animal in each experimental group (two glomeruli
per animal; four animals per group). The glomerular wall was
morphologically separated into six distinct regions for counting:
abluminal and luminal endothelial membranes, abluminal and
luminal podocyte membranes, slit diaphragm, and mesangial cell
plasma membrane. In addition, labelings over the rough ER
and Golgi regions of podocytes, as well as mitochondria were
evaluated. The length of these various plasma membrane domains
as well as those delineating the cellular compartments were
measured and gold particles associated with these membranes
counted. Values are expressed in particles per micrometer. Total
membrane length evaluated varied between 50 and 70 mm per
membrane domain and per animal, except for the slit diaphragm
for which total length per animal was about 30 mm. For the
GBM, the density of labeling was evaluated in relation to its surface
and the results are expressed in number of particles per micrometer
square. Total GBM evaluated was about 25 mm2 per animal, per
condition. Mean values were calculated along with their standard
deviations. Statistical evaluations were carried out using the
Student’s t-test.
Western blotting
Glomerular lysate samples were boiled in reducing sodium dodecyl
sulfate-sample buffer, separated by sodium dodecyl sulfate–poly-
acrylamide gel electrophoresis on 10% polyacrylamide gels, and then
electrophoretically transferred onto nitrocellulose membranes.
For MT1-MMP and furin immunodetection, membranes were
blocked in Tris-buffered saline (50 mM) containing 0.05% Tween 20
and 1% milk for 1 and 3 h, respectively, and then incubated
overnight at 41C with the appropriate antibodies. Antibodies were
revealed with Lumi-Light Plus chemiluminescence detection kit and
results were exposed with Kodak X-Omat-AR films. Gels were then
scanned and band densities evaluated by the Image Quant V1.26
program (NIH).
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